{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037423","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.342908+00:00","generated_at":"2026-06-09T22:36:09.814305+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Propanc Biopharma issues $61K convertible note to GS Capital; conversion at $0.015, adjustable to $0.0075","bullets":["Entered securities purchase agreement with GS Capital Partners, LLC for $61,000 principal convertible note at 8% interest.","Note purchased at $57,500 ($3,500 OID); net proceeds for general working capital.","Conversion price initially $0.015/share, reduced to $0.0075 if stock trades <$0.01 for 5+ consecutive trading days.","Maturity April 12, 2024; prepayment options: 110% within 60 days, scaling to 125% by 180 days.","Events of default include failure to timely issue conversion shares, loss of OTC listing, and non-compliance with SEC reporting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037423","json":"https://secwatch.observer/filing/0001493152-23-037423.json","markdown":"https://secwatch.observer/filing/0001493152-23-037423.md","text":"https://secwatch.observer/filing/0001493152-23-037423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:36:09.814305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06c5cd9b43834e37f901e3ca01011b94fb81cfd1","claim":"Propanc Biopharma, Inc. incurred convertible notes of $61,000 with an investor at 8% per annum maturing April 12, 2024.","evidence_excerpt":"On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$61,000"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"April 12, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"26bb9b0f17359d1df535b18a0050f9ff82f6f75d","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with Investor valued at $61,000 (effective 2023-10-12).","evidence_excerpt":"On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”), for a purchase price of $57,500.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Investor"},{"label":"Value","value":"$61,000"},{"label":"Effective","value":"2023-10-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}